The jury in the second bellwether trial involving a vaginal mesh manufactured by Ethicon has awarded the plaintiff $3.27 million in damages, according to newswire reports and court documents.

Rockville Centre, NY -- (SBWIRE) -- 09/09/2014 -- The second federal bellwether trial involving a vaginal mesh product manufactured by Johnson & Johnson subsidiary Ethicon has concluded, with the jury in the case finding in favor of plaintiff Jo Huskey and awarding her $3.27 million in damages, according to a September 5 Reuters report.* The trial of Huskey v. Ethicon (No. 12-5201; U.S. District Court for the Southern District of West Virginia) began on August 14 and ended after nearly two weeks. According to the Reuters report, "jurors found Ethicon liable for selling faulty devices and failing to warn patients and their doctors that users were at risk from side effects that include pain, bleeding and infection."

The Rottenstein Law Group LLP, a New York-based personal injury law firm representing plaintiffs nationwide in lawsuits against Ethicon, the manufacturer of vaginal mesh devices that have allegedly caused serious injuries to women implanted with the devices as treatments for pelvic organ prolapse (POP) and stress urinary incontinence (SUI), is encouraged by the verdict and the award.

"This outcome sends a message that a company whose product hurts people will be held accountable," said Rochelle Rottenstein, principal of the Rottenstein Law Group. "We're hopeful that this verdict is indicative of further plaintiff's verdicts to follow."

The federal Ethicon multidistrict litigation in West Virginia has consolidated approximately 19,000 lawsuits filed by victims alleging injuries caused by the company's products.

About The Rottenstein Law Group LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

http://www.reuters.com/article/2014/09/05/us-ethicon-mesh-verdict-idUSKBN0H01YA20140905

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Drug manufacturer Bayer has made public plans to launch new studies as a step toward seeking approval of its anticoagulant Xarelto for additional uses.

Rockville Centre, NY -- (SBWIRE) -- 08/29/2014 -- According to a Reuters report, Xarelto manufacturer Bayer is going to be testing the drug—currently very popular as a treatment for preventing strokes—on patients with "embolic stroke of undetermined source and peripheral artery disease" and for long-term prevention in patients who have suffered an acute coronary syndrome."*

"This is troubling," said Rochelle Rottenstein, principal of the Rottenstein Law Group. "The dangers of Xarelto are becoming clearer with each new complaint filed with the FDA and each new lawsuit filed against Bayer. To learn that Bayer is seeking to expand the uses of the embattled drug is disheartening."

In 2013, the U.S. FDA received several hundred adverse event reports submitted by individuals who claimed to have a serious adverse side effect while taking Xarelto (rivaroxaban), as compared to a lower number for Pradaxa (dabigatran).** Data show that the number of persons being prescribed these blood thinning drugs is estimated at about 4 million for the year, with Xarelto prescriptions outnumbering Pradaxa prescriptions by two-to-one.** Anticoagulants (or "blood thinners") are considered high-risk prescription drugs because they can cause excessive internal bleeding and other injuries in some patients.

Anyone needing more information about the dangers of Xarelto should visit http://www.rotlaw.com/xarelto/. Representatives of the Rottenstein Law Group are available to answer any questions, and there is a confidential, no-cost claim evaluation form at the site that can be filled out in order to determine if one has grounds to file a Xarelto lawsuit.

*http://www.reuters.com/article/2014/08/29/bayer-xarelto-idUSF9N0NY07P20140829
**http://www.ismp.org/quarterwatch/pdfs/2013Q1.pdf

ABOUT THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
100 Merrick Road
Suite 226W
Rockville Centre, NY 11570
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The Firm represents women in transvaginal mesh lawsuits who were allegedly harmed by mesh implants marketed by Ethicon, Inc.

Rockville Centre, NY -- (ReleaseWire) -- 08/11/2014 -- The Rottenstein Law Group LLP, a New York-based personal injury law firm representing plaintiffs nationwide in lawsuits against Ethicon, the manufacturer of GYNECARE PROLIFT vaginal mesh devices (http://gynecareproliftmeshlawsuit.net), which have allegedly caused serious injuries to women who were implanted with the devices as treatments for pelvic organ prolapse (POP) and stress urinary incontinence (SUI), is encouraged by the latest order issued by the federal court handling early trials involving the products.

By order issued on August 5 in In re: Ethicon, Inc., Pelvic Repair System Products Liability Litigation (No. 2:12-MD-02327; U.S. District Court for the Southern District of West Virginia at Charleston), United States District Judge Joseph R. Goodwin has scheduled a pretrial conference in the next two bellwether matters (nos. 2:12-cv-05201 and 2:12-cv-09972) for the afternoon of August 13. The court will notify the parties separately of the date and time of a final settlement conference.

"We're keeping a close eye on the Ethicon proceedings because we represent a sizeable group of Ethicon plaintiffs awaiting their days in court," said Rochelle Rottenstein, principal of the Rottenstein Law Group. "The outcomes of these bellwether trials are an important factor in determining how juries will decide future cases. It's encouraging to know that the next set of cases should be going to trial soon."

The federal Ethicon multidistrict litigation (MDL) has consolidated approximately 19,000 lawsuits filed by victims alleging injuries caused by the company's products. The Rottenstein Law Group is currently evaluating Ethicon vaginal mesh claims and encourages anyone who believes they might have cause to file an Ethicon vaginal mesh lawsuit to visit http://www.gynecareproliftmeshlawsuit.net.

The site contains valuable, easy to understand information about the legal process, as well as important information about the severe adverse side effects linked to Ethicon mesh devices. Users of the site can also access a no-cost confidential case evaluation form which will determine whether or not there are grounds to sue Ethicon.

About The Rottenstein Law Group LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:

The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
100 Merrick Road
Suite 226W
Rockville Centre, NY 11570
212-933-9500 (office phone)
212-933-9980 (facsimile)
rochelle@rotlaw.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The firm represents clients in lawsuits against DePuy Orthopaedics who allege that the company’s Pinnacle Hip Replacement System caused them serious health complications.

Rockville Centre, NY -- (ReleaseWire) -- 08/01/2014 -- The Rottenstein Law Group LLP is currently representing plaintiffs with claims stemming from injuries allegedly caused by metal-on-metal DePuy Pinnacle hip replacement devices.

United States District Judge Ed Kinkeade, who is overseeing several lawsuits involving the DePuy Orthopaedics Pinnacle hip implant system (In re: DePuy Orthopaedics, Inc. Pinnacle Hip Implant Products Liability Litigation; United States District Court for the Northern District of Texas, Dallas Division, No. 3:11-MD-2244-K) issued two memorandum opinions on July 18 denying motions of defendant DePuy, making it possible for two individual cases against the company and its parent, Johnson & Johnson, to proceed to trial. (Lay v. DePuy Orthopaedics, Inc., et al., No. 3:11-cv-03590-K; Herlihy-Paoli v. DePuy § Orthopaedics, Inc., et al. No 3:12-cv-04975-K.)

DePuy Orthopaedics had asked the court to exclude the testimony of six potential witnesses in both cases, arguing that the witnesses did not legally qualify as experts. In a separate motion, DePuy had asked the court to dismiss the suits or award DePuy summary judgment or partial summary judgment on some of the plaintiffs' claims. With the denial of the motions, the lawsuits are on track to be the first tried.

"Our firm represents a number of DePuy Pinnacle plaintiffs, so we are eager to have the bellwether trials begin," said Rochelle Rottenstein, principal of the Rottenstein Law Group. "Our goal is to ensure that anyone harmed by a DePuy Pinnacle hip implant receives the compensation they deserve, and the outcomes of these first cases will set the stage for possible settlements of other claims."

The Rottenstein Law Group LLP maintains a website where users can obtain valuable information about the dangers of metal-on-metal hip replacement implants, and research the process of how to go about filing a lawsuit against the medical device manufacturers that sold these dangerous devices. The site, www.hipimplantinjury.com, contains information about dangerous hip implants sold by various manufacturers.

Individuals who feel they have cause to sue DePuy Orthopaedics, or another manufacturer, can fill out the no-cost, confidential claim evaluation form to determine whether or not they have a case.

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
100 Merrick Road
Rockville Centre, NY 11570
212-933-9500
212-933-9980
rochelle@rotlaw.com
plus.google.com/106070664376281033016

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The Rottenstein Law Group, a national personal injury law firm with a new website dedicated to providing the public information about the possible dangers of Xarelto and legal options if they have claims of harms suffered, notes an significant increase in the number of Xarelto injuries reported to the U.S. FDA.

Rockville Centre, NY -- (ReleaseWire) -- 07/30/2014 -- In 2013, the U.S. FDA received several hundred adverse event reports submitted by individuals who claimed to have a serious adverse side effect while taking Xarelto (rivaroxaban) (www.xareltoinjuryfirm.com), as compared to a lower number for Pradaxa (dabigatran).* Data show that the number of persons being prescribed these blood thinning drugs is estimated at about 4 million for the year, with Xarelto prescriptions outnumbering Pradaxa prescriptions by two-to-one.* Anticoagulants (or "blood thinners") are considered high-risk prescription drugs because they can cause excessive internal bleeding and other injuries in some patients.

"We are of course concerned about the increasing number of adverse events reportedly associated with Xarelto," said Rochelle Rottenstein, principal of the Rottenstein Law Group. "Our goal is to make it as easy as possible for anyone possibly harmed by Xarelto to learn about those dangers and about legal options for demanding compensation for injuries suffered."

Anyone needing more information about the dangers of Xarelto should visit the firm's new site, where everything is explained in clear, concise language. Representatives of the firm are available to answer any questions, and there is a confidential, no-cost claim evaluation form that can be filled out in order to determine if there are grounds to file a Xarelto lawsuit.

*http://www.ismp.org/quarterwatch/pdfs/2013Q1.pdf

About The Rottenstein Law Group LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
100 Merrick Road
Suite 226W
Rockville Centre, NY 11570
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The Rottenstein Law Group, a national personal injury law firm, has launched a new website dedicated to providing the public information about the possible dangers of Xarelto and legal options if they have claims of harms suffered.

Rockville Centre, NY -- (ReleaseWire) -- 07/28/2014 -- The new site, www.xareltoinjuryfirm.com, offers comprehensive information about the severe adverse side effects associated with Xarelto. Like similar so-called "blood thinners" (anticoagulants), Xarelto carries a risk of internal bleeding (hemorrhaging) side effects, according to the U.S. Food and Drug Administration (FDA). Xarelto's internal bleeding side effects cannot be controlled or reversed by physicians, however, making the drug more dangerous than other, conventional anticoagulants, such as warfarin (Coumadin).

"We have heard allegations that Xarelto's manufacturers should have recalled the product when they learned about the substantial dangers," said Rochelle Rottenstein, principal of the Rottenstein Law Group. "Our goal is to make it as easy as possible for anyone possibly harmed by Xarelto to learn about those dangers and about legal options for demanding compensation for injuries suffered."

In 2013, the U.S. FDA received several hundred adverse event reports submitted by individuals who claimed to have a serious adverse side effect while taking Xarelto (rivaroxaban), as compared to a lower number for Pradaxa (dabigatran). Data show that the number of persons being prescribed these blood thinning drugs is estimated at about 4 million for the year, with Xarelto prescriptions outnumbering Pradaxa prescriptions by two-to-one.*

Xarelto is a frequently prescribed blood thinner that has been associated with uncontrolled bleeding in the body's vital organs, according to reports to the U.S. FDA. Worse, this internal bleeding can be so severe that it can lead to stroke or death. Data show that the U.S. FDA received almost 700 adverse event reports associated with Xarelto in 2013 documenting injuries sustained by patients who were prescribed the drug by physicians.* Anticoagulants—or "blood thinners"— are typically a high risk drug, although they are widely prescribed to help prevent blood clots that can lead to heart attacks and strokes in some patients.

Anyone needing more information about the dangers of Xarelto should visit the site, where everything is explained in clear, concise language. Representatives of the firm are available to answer any questions, and there is a confidential, no-cost claim evaluation form that can be filled out in order to determine if there are grounds to file a Xarelto lawsuit.

*http://www.ismp.org/quarterwatch/pdfs/2013Q1.pdf

About The Rottenstein Law Group LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
100 Merrick Road
Suite 226W
Rockville Centre, NY 11570
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The Firm represents men who claim that testosterone product use has caused them to suffer strokes or heart attack.

Rockville Centre, NY -- (ReleaseWire) -- 07/23/2014 -- In light of the growing concern about the dangers of prescription testosterone products, the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee for September 17.* The published agenda states: "The committees will discuss the appropriate indicated population for testosterone replacement therapy and the potential for adverse cardiovascular outcomes associated with this use." The Rottenstein Law Group, a national personal injury law firm, earlier this year launched a new website, at www.testosteroneinjuryfirm.com, dedicated to helping men get more information about the dangers of popular, but often unnecessary, testosterone treatments.

Millions of prescriptions have been written by doctors for testosterone products and supplement brands, to treat what has become known as "Low T." Low T is characterized in marketing campaigns as a disorder that strikes middle-aged men. The symptoms include fatigue, depression and a diminished sex drive. Some men, who otherwise were in good health, suffered heart attacks and strokes after using the products. After falling ill, they discovered that testosterone products significantly increase the risk of heart attacks and strokes, but they were not warned by their doctors or the manufacturers. The failure on the part of doctors and drug companies to warn about these risks has lead to the filing of personal injury lawsuits.

"We are concerned that testosterone products are being overprescribed, putting many men at risk of being injured," said Rochelle Rottenstein, principal of the Rottenstein Law Group. "We want to make it as easy as possible for men who believe they have been harmed to seek the compensation they might deserve."

Anyone needing more information about the dangers of testosterone products should visit the site, where everything is explained in clear, concise language. Representatives of the firm are available to answer any questions, and there is a confidential, no-cost claim evaluation form that can be filled out in order to determine if there are grounds to file a testosterone products lawsuit.

- http://www.fda.gov/AdvisoryCommittees/Calendar/ucm404905.htm

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The Firm represents women in transvaginal mesh lawsuits who were allegedly harmed by mesh implants marketed by C.R. Bard, Inc.

Rockville Centre, NY -- (ReleaseWire) -- 07/09/2014 -- Pending transvaginal mesh lawsuits that have been consolidated into a multidistrict litigation involving C.R. Bard (In re: C.R. Bard, Inc., Pelvic Repair Systems Products Liability Litigation – MDL No. 2187) continue to move through pretrial proceedings with the latest Order dated July 2, 2014 stating that the Court will hear oral arguments on a plaintiffs' motion to amend a previous pretrial order (Stipulated Evidence Preservation Protocol for Potential Trial Selection Cases, Order No. 121), on Wednesday, July 9. The hearing will take place via telephone before a U.S. Magistrate Judge in the U.S. District Court for the Southern District of West Virginia, where the MDL is being overseen.

The Rottenstein Law Group LLP represents plaintiffs with claims of harm stemming from the implantation of C.R. Bard Avaulta transvaginal mesh devices, which were meant to address symptoms of pelvic organ prolapse (POP), and stress urinary incontinence (SUI) in women who have given birth to children, or are suffering from weakened pelvic muscles as they go through menopause.

"Our firm is pleased to see the legal process move forward so our clients can have their day in court," said Rochelle Rottenstein, principal of the Rottenstein Law Group. "We want to ensure that our clients receive the compensation they deserve for their injuries, medical expenses and other damages."

Current court records indicate that there are just over 9,000 lawsuits pending against C.R. Bard, alleging that the company marketed and sold a defective product which caused women to suffer a number of severe adverse side effects including erosion, chronic pain, infections, and scarring.

The Rottenstein Law Group encourages those who feel they might have cause to file a lawsuit against C.R. Bard or another transvaginal mesh manufacturer to visit the firm's Web site, www.meshinjurylawfirm.com, for valuable, concise information about the dangers of transvaginal mesh, and a no-cost, confidential case evaluation form that will determine if individuals have grounds to seek compensation for injuries.

ABOUT THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
100 Merrick Road
Suite 226W
Rockville Centre, NY 11570
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
plus.google.com/106070664376281033016

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The firm is actively filing lawsuits on behalf of men who developed gynecomastia allegedly as a result of Risperdal use.

Rockville Centre, NY -- (SBWIRE) -- 05/13/2014 -- The Rottenstein Law Group LLP, a national personal injury law firm which maintains a Risperdal lawsuit informational web site at www.risperdallawsuit.us, notes the call for physician participation by researchers who are compiling a registry of the use of atypical antipsychotic medications like Risperdal by pregnant women. The researchers are attempting to establish a link between the drugs and birth defects, as the use of these medications by pregnant women is increasing.

According to an April 18, 2014 article published in the journal Clinical Psychiatry News, researchers are attempting to establish a clear link between the use of atypical antipsychotic medications like Risperdal, and the occurrence of certain birth defects. The article mentions a previous study that was published in August 2013 in the Journal of Clinical Psychopharmacology that found that mothers treated with Risperdal or another drug in the atypical antipsychotic class, were twice as likely to have a child with birth defects, than women who did not use the drugs during their pregnancies. Research from another study published in the British Medical Journal's "Open," earlier that year, found no such link. Physician participation would assist the researchers by supplying the information they need to compile more accurate data.*

Risperdal has been making news recently for its alleged link to a condition known as gynecomastia, which is characterized by the abnormal growth of breast tissue in men and boys who take the drug. Hundreds of lawsuits have been filed by plaintiffs alleging that Janssen Pharmaceuticals, the maker of the drug, concealed information from physicians and consumers about this potential side effect. Three hundred and fifty of these lawsuits have been consolidated into a mass tort litigation currently underway in the Philadelphia Court of Common Pleas (Risperdal Litigation, Case No. 100300296).

The Rottenstein Law Group LLP encourages those who believe they or their loved ones have suffered from the alleged side effects of Risperdal to visit the firm's Web site to learn about Risperdal lawsuits and side effects.

* http://www.clinicalpsychiatrynews.com/single-article/more-conclusive-link-needed-on-teratogenicity-and-atypicals-in-pregnancy/4d91f10eb4cf78322f908e2cfe59436e.html

About Rottenstein Law Group LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
100 Merrick Road
Suite 226W
Rockville Centre, NY 11570
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
plus.google.com/106070664376281033016

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm